48 results about "Multi resistant bacteria" patented technology

The invention relates to a kind of intestinal mucosa damage restoring agent as well as preparative method. It has solved many defects of traditional method such as no obvious therapeutic efficacy of digallic acid soybean protein to diarrhea caused by bacteria, fungus, virus, toxins and parasites, the increase of drug resistant strain and multidrug resistant strain, the increase of chemical resistance and drug tolerance of pathogenic bacteria. The product in the invention contains 15-100% (by weight) of digallic acid antimicrobial active protein. The preparing method of the invention: adopting digallic acid to load antimicrobial active protein. The total efficiency of the agent can reach 100%, the diarrhea symptoms of patients can be substantially released after 1 day of taken the medicine, after 2-3 days, the cure rate can reach 85% or more. The yield of the antimicrobial active protein in the invention is 80% or higher by weight.

A compound represented by the following general formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition thereof, and the use thereof to prevent or treat infectious diseases and a method to prevent or treat infectious diseases using those regimen are disclosed. The compound represented by formula (I) has an antibacterial activity against both gram-positive and gram-negative bacteria, and is useful in the prevention or treatment of infectious diseases caused by these bacteria.

The invention belongs to the technical field of medical materials and particularly relates to an organic / inorganic combined antibacterial composition and a preparation method and application thereof.The organic / inorganic combined antibacterial composition comprises nano-copper, tigecycline and polydopamine; the compound of inorganic antibacterial agent nanometer copper and organic antibiotic tigecycline is wrapped by polydopamine to produce the produce. The results show that the product has good resistance to multi-drug resistant bacteria and is attached to the surface of a catheter after air drying and filming, slow release of the antibacterial agent is achieved, and technical shortcomings that single antibactic has poor antibacterial effect, low antibacterial duration and easy sheddingof spraying composite films.

The present invention relates to new oxazolidinone compounds of general formula (I) having antibiotic activity even against multiresistant bacterial strains (I).

This invention pertains to a crystalline compound of Formula (A) as described herein and compositions containing this crystalline compound, as well as methods of using the compound or pharmaceutical compositions comprising it to treat bacterial infections. The compound and compositions are especially useful to treat Gram negative bacterial infections, including multi-drug resistant strains.

The invention discloses a compound YT-011 resisting multi-drug resistant bacteria and a preparation method thereof. The compound YT-011 has an important supporting effect on the discovery of drugs resisting drug resistant bacteria based on a pathogenic mechanism. A technology for preparing an antibacterial active substance having a novel structure through a structure-modified microorganism-derived active mother nucleus is used as a key technology. The compound YT-011 provides a feasible method for the discovery of the innovative drug. The microorganism-derived physiological active substance having structural diversity increases the discovery ways of innovative drugs, and enriches the research and development ideas.

The invention discloses a lactic acid bacteria strain with broad-spectrum inhibition of multi-drug-resistant food-borne pathogenic bacteria and its application; Bacillus GS083, Lactobacillus plantarum GS086, Lactobacillus plantarum GS090 and Lactobacillus fermentum GF110. The lactic acid bacteria strain provided by the invention has good antibacterial effect on multidrug-resistant bacteria and food-borne pathogenic bacteria, and can inhibit both Gram-negative bacteria and Gram-positive bacteria; the bacterial strain also has bile salt The characteristics of hydrolase activity, acid resistance and bile salt resistance, low drug resistance, no hemolysis, and no virulence genes enrich the resource bank of lactic acid bacteria, and have broad application prospects in food, cosmetics, pharmaceuticals and other industries.

The invention relates to a small peptide resisting MDR (multiple resistant bacteria). The small peptide is characterized in that the small peptide has the function of resisting clinically isolated MDR. In-vitro activity assay results prove that 11 small peptides have different antibacterial activities for multiple MDR and have the MIC value ranging from 4 mu g / L to 128 mu g / L according to different bacteria. Compared with a mother pattern, the small peptide has enhanced pseudomonas aeruginosa and candida albicans resistant activity. 6 peptides with better antibacterial activity are selected for an in vivo experiment, results prove that the 6 peptides can notably reduce the death rate of a model mouse because of a pseudomonas aeruginosa standard strain and clinical pan-drug-resistant pseudomonas aeruginosa septicemia and have a synergistic effect with polymyxin; no hemolytic reaction is caused when the concentration of 6 small peptides is 10 mg / ml, and the product safety is higher; local stimulation experiment results of rabbit eye conjunctiva show that the small peptide has no acute toxic stimulus reaction.

The invention relates to a synthesis method of minocycline and substituted minocycline, in particular to the synthesis of 9-aminominocycline. 9‑Aminominocycline is an important variant of tigecycline, which is used for the control of multidrug-resistant bacteria. The raw material of the invention is easy to obtain, the synthesis route is short, the reaction conditions are mild, the yield is high, the process is simple, and the method is suitable for large-scale production.